ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 103 citations in OpenAlex.
- Protective Immunity and New Vaccines for Lyme Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.Clinical and vaccine immunology : CVI · 2014Trial
- Clinical Features and Outcomes of Pediatric Lyme Arthritis in Europe: A Large Swiss Cohort Study.Open forum infectious diseases · 2026Article
- Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice.NPJ vaccines · 2026Article
- Aspects of the Immunopathogenesis of Lyme Arthritis.Microorganisms · 2025Review
- Novel recombinant vaccinia virus-vectored vaccine affords complete protection against homologousEmerging microbes & infections · 2024Article
- Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease.Antibodies (Basel, Switzerland) · 2023Review
- Development of an mRNA-lipid nanoparticle vaccine against Lyme disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Profiling disease burden and Borrelia seroprevalence in Canadians with complex and chronic illness.PloS one · 2023Article
- Transmission Cycle of Tick-Borne Infections and Co-Infections, Animal Models and Diseases.Pathogens (Basel, Switzerland) · 2022Review
- Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.Expert review of vaccines · 2022Review
- Lyme Arthritis.Infectious disease clinics of North America · 2022Review
- CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance.Infection and immunity · 2022Article
- The year that shaped the outcome of the OspA vaccine for human Lyme disease.NPJ vaccines · 2022Review
- Human and Veterinary Vaccines for Lyme Disease.Current issues in molecular biology · 2021Article
- Article
- iLBE for Computational Identification of Linear B-cell Epitopes by Integrating Sequence and Evolutionary Features.Genomics, proteomics & bioinformatics · 2020Article
- Protection againstHuman vaccines & immunotherapeutics · 2020Article
- Self-analysis of repeat proteins reveals evolutionarily conserved patterns.BMC bioinformatics · 2020Article
- Design of a broadly reactive Lyme disease vaccine.NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Antibiotic-refractory Lyme arthritis may result from Borrelia burgdorferi-induced autoimmunity in affected joints. Such patients usually have certain HLA-DRB1 molecules that bind an epitope of B. burgdorferi outer-surface protein A (OspA₁₆₃₋₁₇₅), and cellular and humoral immune responses to OspA are greater in patients with antibiotic-refractory arthritis than in those with antibiotic-responsive arthritis. Recent work in a mouse model suggests that, during B. burgdorferi infection, OspA in genetically susceptible individuals stimulates a particularly strong T(H)1 response, which may be one of several factors that can help set the stage for a putative autoimmune response in affected joints. However, vaccination with OspA did not induce arthritis in this mouse model, and case and control comparisons in human vaccine trials did not show an increased frequency of arthritis among OspA-vaccinated individuals. Thus, a vaccine-induced immune response to OspA does not replicate the sequence of events needed in the natural infection to induce antibiotic-refractory Lyme arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.